Sunitinib

Generic Name
Sunitinib
Brand Names
Sutent, Sunitinib Accord
Drug Type
Small Molecule
Chemical Formula
C22H27FN4O2
CAS Number
557795-19-4
Unique Ingredient Identifier
V99T50803M
Background

Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formul...

Indication

Sunitinib is indicated for the following conditions:

Associated Conditions
Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
Associated Therapies
-
Clinical Trials
Related News

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

First Posted Date
2024-04-30
Last Posted Date
2024-11-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
35
Registration Number
NCT06390826
Locations
🇺🇸

ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Not Applicable
Not yet recruiting
Conditions
Renal Cell Carcinoma
Interventions
Drug: Sunitinib
First Posted Date
2023-09-13
Last Posted Date
2023-09-13
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
488
Registration Number
NCT06032728

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

First Posted Date
2023-07-18
Last Posted Date
2023-11-29
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
30
Registration Number
NCT05949424
Locations
🇳🇱

University Medical Center Groningen, Groningen, Netherlands

A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

First Posted Date
2023-02-27
Last Posted Date
2024-08-05
Lead Sponsor
Pfizer
Target Recruit Count
376
Registration Number
NCT05745142
Locations
🇹🇷

Pfizer, Istanbul, Turkey

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Phase 3
Recruiting
Conditions
GIST
Interventions
Drug: Sunitinib
Drug: Ripretinib
First Posted Date
2023-02-17
Last Posted Date
2024-12-11
Lead Sponsor
Deciphera Pharmaceuticals, LLC
Target Recruit Count
54
Registration Number
NCT05734105
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇨🇦

Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada

🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 60 locations

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

First Posted Date
2023-01-18
Last Posted Date
2024-12-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
24
Registration Number
NCT05687123
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

Memorial Hospital East, Shiloh, Illinois, United States

🇺🇸

Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States

and more 5 locations

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

First Posted Date
2023-01-10
Last Posted Date
2024-12-17
Lead Sponsor
Exelixis
Target Recruit Count
291
Registration Number
NCT05678673
Locations
🇺🇸

Exelixis Clinical Site #164, Newport Beach, California, United States

🇺🇸

Exelixis Clinical Site #162, San Francisco, California, United States

🇺🇸

Exelixis Clinical Site #163, Aurora, Colorado, United States

and more 161 locations

Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

First Posted Date
2022-07-28
Last Posted Date
2024-11-13
Lead Sponsor
RayzeBio, Inc.
Target Recruit Count
288
Registration Number
NCT05477576
Locations
🇪🇸

Research Facility, Zaragoza, Spain

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

First Posted Date
2022-05-09
Last Posted Date
2024-10-26
Lead Sponsor
University of Miami
Target Recruit Count
48
Registration Number
NCT05366816
Locations
🇺🇸

University of Miami, Miami, Florida, United States

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

First Posted Date
2022-02-18
Last Posted Date
2024-08-07
Lead Sponsor
Taiho Pharmaceutical Co., Ltd.
Target Recruit Count
78
Registration Number
NCT05245968
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

🇨🇳

Fudan University, Shanghai Cancer Center, Shanghai, China

🇯🇵

Kumamoto University Hospital, Kumamoto, Japan

and more 11 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy